Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Eosinophilic Asthma (MEMORY)
NCT02594332Phase 3Terminated
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Nov 2015
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic asthma (EA), sponsored by Johannes Gutenberg University Mainz. Started Nov 2015; status: terminated.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT02594332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594332.